Phase I, single-dose, dose-escalating study of inhaled dry powder capreomycin: A new approach to therapy of drug-resistant tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 6, 2013, Pages 2613-2619

  Dharmadhikari, Ashwin S ^a   Kabadi, Mohan ^b   Gerety, Bob ^b   Hickey, Anthony J ^c   Fourie, P Bernard ^d   Nardell, Edward ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Medicine in Need   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

CAPREOMYCIN;

ADULT; ARTICLE; CHEST TIGHTNESS; COUGHING; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MIGRAINE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SINGLE DRUG DOSE; TREATMENT RESPONSE; VOMITING;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; ANTITUBERCULAR AGENTS; CAPREOMYCIN; DRUG DELIVERY SYSTEMS; DRY POWDER INHALERS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; POWDERS; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 84877855898     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02346-12     Document Type: Article

References (33)

1. World Health Organization. 2011. WHO report 2011: Global tuberculosis control. World Health Organization, Geneva, Switzerland. http://www .who.int/tb/publications/global-report/2011/gtbr11-full.pdf.
2. Institute of Medicine. 2012. Facing the reality of drug-resistant tuberculosis in India: Challenges and potential solutions. Summary of a joint workshop. National Academies Press, Washington, DC.
3. World Health Organization. 2009. WHO report 2009: Management of MDR-TB. A field guide. World Health Organization, Geneva, Switzerland. http://whqlibdoc.who.int/publications/2009/9789241547765-eng .pdf.
4. Jeon DS, Shin DO, Park SK, Seo JE, Seo HS, Cho YS, Lee JY, Kim DY, Kong SJ, Kim YS, Shim TS. 2011. Treatment outcome and mortality among patients with multidrug-resistant tuberculosis in tuberculosis hospitals of the public sector. J. Korean Med. Sci. 26:33-41.
5. Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, Moll AP, Gandhi NR, Galvani AP. 2009. Treatment outcomes among patients with multidrug-resistant tuberculosis: Systematic review and meta-analysis. Lancet Infect. Dis. 9:153-161.
6. Tabarsi P, Chitsaz E, Baghaei P, Shamaei M, Farnia P, Marjani M, Kazempour M, Amiri M, Mansouri D, Masjedi MR, Velayati AA, Caminero JA. 2010. Impact of extensively drug-resistant tuberculosis on treatment outcome of multidrug-resistant tuberculosis patients with standardized regimen: Report from Iran. Microb. Drug Resist. 16:81-86.
7. Donald PR, Sirgel FA, Venter A, Smit E, Parkin DP, Van de Wal BW, Mitchison DA. 2001. The early bactericidal activity of amikacin in pulmonary tuberculosis. Int. J. Tuberc. Lung Dis. 5:533-538.
8. Heifets L, Simon J, Pham V. 2005. Capreomycin is active against nonreplicating M. tuberculosis. Ann. Clin. Microbiol. Antimicrob. 4:6.
9. Braude AC, Hornstein A, Klein M, Vas S, Rebuck AS. 1983. Pulmonary disposition of tobramycin. Am. Rev. Respir. Dis. 127:563-565.
10. Carcas AJ, Garcia-Satue JL, Zapater P, Frias-Iniesta J. 1999. Tobramycin penetration into epithelial lining fluid of patients with pneumonia. Clin. Pharmacol. Ther. 65:245-250.
11. Valcke YJ, Vogelaers DP, Colardyn FA, Pauwels RA. 1992. Penetration of netilmicin in the lower respiratory tract after once-daily dosing. Chest 101:1028-1032.
12. Reisfeld B, Metzler CP, Lyons MA, Mayeno AN, Brooks EJ, Degroote MA. 2012. A physiologically based pharmacokinetic model for capreomycin. Antimicrob. Agents Chemother. 56:926-934.
13. Heifets L, Lindholm-Levy P. 1989. Comparison of bactericidal activities of streptomycin, amikacin, kanamycin, and capreomycin against Mycobacterium avium and M. tuberculosis. Antimicrob. Agents Chemother. 33:1298-1301.
14. Deziel-Evans LM, Murphy JE, Job ML. 1986. Correlation of pharmacokinetic indices with therapeutic outcome in patients receiving aminoglycosides. Clin. Pharm. 5:319-324.
15. Moore RD, Lietman PS, Smith CR. 1987. Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration. J. Infect. Dis. 155:93-99.
16. Ryan G, Singh M, Dwan K. 2011. Inhaled antibiotics for long-term therapy in cystic fibrosis. Cochrane Database Syst. Rev. 2011:CD001021. doi:10.1002/14651858.CD001021.pub2.
17. Rubin BK. 2008. Aerosolized antibiotics for non-cystic fibrosis bronchiectasis. J. Aerosol Med. Pulm. Drug Deliv. 21:71-76.
18. Corcoran TE. 2009. Aerosol drug delivery in lung transplant recipients. Expert Opin. Drug Deliv. 6:139-148.
19. Crowder TM, Rosati JA, Schroeter JD, Hickey AJ, Martonen TB. 2002. Fundamental effects of particle morphology on lung delivery: Predictions of Stokes' law and the particular relevance to dry powder inhaler formulation and development. Pharm. Res. 19:239-245.
20. Muttil P, Wang C, Hickey AJ. 2009. Inhaled drug delivery for tuberculosis therapy. Pharm. Res. 26:2401-2416.
21. Fiegel J, Garcia-Contreras L, Thomas M, VerBerkmoes J, Elbert K, Hickey A, Edwards D. 2008. Preparation and in vivo evaluation of a dry powder for inhalation of capreomycin. Pharm. Res. 25:805-811.
22. Elsevier. 2008. Capreomycin. Tuberculosis (Edinb.) 88:89-91.
23. Shin S, Furin J, Alcantara F, Hyson A, Joseph K, Sanchez E, Rich M. 2004. Hypokalemia among patients receiving treatment for multidrugresistant tuberculosis. Chest 125:974-980.
24. Garcia-Contreras L, Fiegel J, Telko MJ, Elbert K, Hawi A, Thomas M, VerBerkmoes J, Germishuizen WA, Fourie PB, Hickey AJ, Edwards D. 2007. Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model. Antimicrob. Agents Chemother. 51: 2830-2836.
25. Louey MD, Van Oort M, Hickey AJ. 2004. Aerosol dispersion of respirable particles in narrow size distributions produced by jet-milling and spray-drying techniques. Pharm. Res. 21:1200-1206.
26. Rastogi N, Labrousse V, Goh KS. 1996. In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages. Curr. Microbiol. 33:167-175.
27. Garcia-Contreras L, Muttil P, Fallon JK, Kabadi M, Gerety R, Hickey AJ. 2012. Pharmacokinetics of sequential doses of capreomycin powder for inhalation in guinea pigs. Antimicrob. Agents Chemother. 56:2612-2618.
28. Black HR, Griffith RS, Brickler JF. 1963. Preliminary laboratory studies with capreomycin. Antimicrob. Agents Chemother. (Bethesda) 161:522-529.
29. Black HR, Griffith RS, Peabody AM. 1966. Absorption, excretion and metabolism of capreomycin in normal and diseased states. Ann. N. Y. Acad. Sci. 135:974-982.
30. Konig P, Gayer D, Kantak A, Kreutz C, Douglass B, Hordvik NL. 1988. A trial of metaproterenol by metered-dose inhaler and two spacers in preschool asthmatics. Pediatr. Pulmonol. 5:247-251.
31. O'Callaghan C, Everard ML, Bush A, Hiller EJ, Ross-Russell R, O'Keefe P, Weller P. 2002. Salbutamol dry powder inhaler: Efficacy, tolerability, and acceptability study. Pediatr. Pulmonol. 33:189-193.
32. Vichyanond P, Phanichyakarn P, Omar AH, Tam A, Wong E. 1994. Ease of handling and efficacy of Bricanyl Turbuhaler in Asian asthmatic children. Asian Pac. J. Allergy Immunol. 12:1-6.
33. Williams J, Richards KA. 1997. Ease of handling and clinical efficacy of fluticasone propionate Accuhaler/Diskus inhaler compared with the Turbohaler inhaler in paediatric patients. UK Study Group. Br. J. Clin. Pract. 51:147-153.